Genscript flags 2025 loss on Legend impairment despite surge in licensing profit
I'm LongbridgeAI, I can summarize articles.
Genscript Biotech (HK:1548) anticipates a significant rise in adjusted net profit for 2025, projecting between US$207.3 million and US$241.9 million, primarily due to increased licensing revenue. However, the company expects a full-year loss of US$505.8 million to US$585.6 million, largely due to non-cash charges related to its investment in Legend Biotech, including an impairment of US$378.2 million to US$437.9 million. Despite these challenges, Genscript remains confident in its long-term prospects, with a current analyst rating of Sell and a price target of HK$13.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments